228 related articles for article (PubMed ID: 16603583)
1. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
4. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.
Parke FA; Reveille JD
Arthritis Rheum; 2004 Oct; 51(5):800-4. PubMed ID: 15478165
[TBL] [Abstract][Full Text] [Related]
7. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
Cansu DU; Kalifoglu T; Korkmaz C
J Rheumatol; 2008 Mar; 35(3):421-4. PubMed ID: 18203328
[TBL] [Abstract][Full Text] [Related]
8. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.
Li S; Kaur PP; Chan V; Berney S
Clin Rheumatol; 2009 Jul; 28(7):787-91. PubMed ID: 19291350
[TBL] [Abstract][Full Text] [Related]
9. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
10. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
11. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
12. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B.
Benucci M; Manfredi M; Mecocci L
J Clin Rheumatol; 2008 Aug; 14(4):245-6. PubMed ID: 18766129
[No Abstract] [Full Text] [Related]
13. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
14. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.
Peterson JR; Hsu FC; Simkin PA; Wener MH
Ann Rheum Dis; 2003 Nov; 62(11):1078-82. PubMed ID: 14583571
[TBL] [Abstract][Full Text] [Related]
15. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients.
Ballanti E; Conigliaro P; Chimenti MS; Kroegler B; Di Muzio G; Guarino MD; Triggianese P; Gigliucci G; Novelli L; Barbato C; Perricone R
Drug Dev Res; 2014 Nov; 75 Suppl 1():S42-5. PubMed ID: 25381975
[TBL] [Abstract][Full Text] [Related]
16. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
17. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
18. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy.
Wendling D; Di Martino V; Prati C; Toussirot E; Herbein G
Joint Bone Spine; 2009 May; 76(3):308-11. PubMed ID: 19346146
[TBL] [Abstract][Full Text] [Related]
19. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]